- As players find larger molecules and drugs more and more difficult to find. Peptide drugs have attracted the attention of the industry again because of its short R & D cycle and low cost.
- The reason is that the short half-life of peptide and the lack of large peptide library are the bottlenecks restricting the development of this field.
- Our team has basically worked in basic research and cro services for many years.
- Our earliest ideas were all aimed at the global pharmaceutical companies, but the domestic development in recent years was a bit unexpected.
- Peptide new drugs are mainly developed by foreign companies, including some pharmaceutical giants such as Pfizer and Merck, but cro / cdmo companies are still the main ones in China
As players find larger molecules and drugs more and more difficult to find. Peptide drugs have attracted the attention of the industry again because of its short R & D cycle and low cost.
At present, there are more than 190 kinds of peptide drugs on the market in the world. In 2019 alone, its sales reached $44 billion.
It includes heavyweight products above the level of US $1 billion, such as gratirel and liraglutide.
According to the prediction of reaearch and markets, the global peptide drug market will exceed $60 billion in 2026.
However, compared with small molecular and macromolecular drugs, peptide drugs only account for 3% of the market share, and few players enter the game.
The reason is that the short half-life of peptide and the lack of large peptide library are the bottlenecks restricting the development of this field.
The short half-life of peptides seriously limits the formation of drug properties of peptides. However, the traditional discovery of new polypeptides is based on the structural transformation of natural peptides, which requires a lot of manpower, time and cost.
Chengdu suno biotechnology has more than 20 years of experience in peptide chemical synthesis, peptide biosynthesis, peptide drug design, peptide reagent development and production, and is the inventor of several patents.
“The lack of large peptide library is the pain point of new peptide discovery”
In the process of polypeptide drug service, we feel that the customer’s pain point in the field of peptide drug discovery is the lack of large peptide library, so we need to design, customize, synthesize, and then test, which has a relatively long period. Therefore, we have been thinking about how to shorten the period of peptide new drug discovery.
Our team has basically worked in basic research and cro services for many years.
Compared with small molecule drugs, peptide has higher specificity and less side effects; compared with macromolecular drugs, the production cost is relatively low, and some targets are not suitable for macromolecular drugs.
In terms of policies and regulations, it will be relatively easy to declare, especially to build a GMP workshop. It is also noted that the competition for macromolecular drugs is very fierce. However, the development of small molecule drugs has encountered some bottlenecks.
Our earliest ideas were all aimed at the global pharmaceutical companies, but the domestic development in recent years was a bit unexpected.
The main reason is that national policies encourage innovative drugs.
Traditional generic pharmaceutical enterprises and Chinese patent medicine enterprises have a strong desire to transform into innovative drugs. In foreign countries, on the one hand, the decision-making cycle of large pharmaceutical enterprises is relatively long; on the other hand, the epidemic situation in foreign countries is relatively serious. Chengdu shengnuo biotechnology is a global pharmaceutical R & D enterprise.
Peptide new drugs are mainly developed by foreign companies, including some pharmaceutical giants such as Pfizer and Merck, but cro / cdmo companies are still the main ones in China
Not only peptide new drugs, but in fact, most of the research and development of new drugs are developed by foreign pharmaceutical companies or some biotechnology companies abroad.
It is only in the last ten years that China’s innovative medicine has really begun to be made. In my opinion, polypeptide is still a minority drug. In the global drug market, the market share is still very small, only about 3%.
We believe that if we solve these two bottlenecks in peptide discovery, the market share of peptide drugs will be greatly increased, which is something we are very confident about.
In China, from our experience in BD this year, many pharmaceutical companies are willing to lay out peptide fields. This is a very good information and environment for us.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……